Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)

Diabetes Care

Volumn 25, Issue 2, 2002, Pages 330-336

  Wright, Alex ^a   Burden, A C Felix ^b   Paisey, Richard B ^c   Cull, Carole A ^d,e   Holman, Rury R ^d  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c TORBAY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; UNITED KINGDOM;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 0036483958     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.2.330     Document Type: Article

References (14)

1. UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. UKPDS Group: UK Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
3. UKPDS Group: UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
4. UKPDS Group: UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Mem Med 124:136-145, 1996
5. Turner RC, Holman RR, Matthews DR: Sulphonylurea failure and inadequacy: "non-insulin diabetes mellitus". In Proceedings of the 13th IDF Conference, Hamilton Island, Australia, 26-28 1988. Cameron D, Colagiuri S, Heding L, Kuhl C, Ma A, Mortimer R, Eds. Causeway Bay, Hong Kong, Excerpta Medica Asia, 1989.
6. UKPDS Group: UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877-890, 1991
7. Johnson JL, Wolf SL, Kabadi UM: Efficacy of insulin and sulphonylurea combination therapy in type II diabetes: a meta-analysis of the randomised placebocontrolled trials. Arch Intern Med 156:259-264, 1996
8. Holman RR, Turner RC: A practical guide to basal and prandial insulin therapy. Diabetic Medicine 5:45-53, 1985
9. UKPDS Group: UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544, 1994
10. SAS Institute: Statistical Analysis System. 6th ed. Cary, NC, SAS Institute, 1990
11. Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 21:1052-1057, 1998
12. UKPDS Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405-412, 2000
13. Holman RR, Steemson J, Turner RC: Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med 4:457-462, 1987
14. Shank ML, Prato SD, DeFronzo RA: Bed-time insulin/daytime glipizide: effective therapy for sulforiylurea failures in MIDDM. Diabetes 44:165-172, 1995